Arena begins ADVISE clinical trial for etrasimod in atopic dermatitis
Arena Pharmaceuticals has dosed the first subject in the phase 2 ADVISE clinical trial, which is evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis (AD). Etrasimod is a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator. Atopic dermatitis is considered to be a serious, chronic immune-mediated disease in which symptoms are varied. However, the usual […]